DN-2024005

DN-2024005 is a small molecule drug candidate being developed by Daehan Nupharm for the treatment of gastroesophageal reflux disease (GERD). As a pipeline asset from a South Korean pharmaceutical company specializing in incrementally modified drugs (IMDs), DN-2024005 is designed to manage acid-related gastrointestinal disorders. While specific chemical details are often proprietary in early pipeline stages, GERD treatments in this class typically function by inhibiting the H+/K+-ATPase enzyme (the proton pump) in gastric parietal cells, thereby suppressing the secretion of gastric acid. The development of DN-2024005 likely involves a novel formulation or a combination of established agents intended to improve therapeutic outcomes, such as faster onset of action or enhanced patient compliance, compared to existing proton pump inhibitors (PPIs) or potassium-competitive acid blockers (P-CABs).